title: Can gadolinium be safely given in renal failure?
authors.affiliation: Massachusetts General Hospital, Boston, MA 02114, USA.
authors.forename: R
authors.initials: R
authors.lastname: Weissleder
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced*; D003287:Contrast Media / Q000009:adverse effects* / Q000493:pharmacokinetics; D003404:Creatinine / Q000652:urine; D004338:Drug Combinations; D005682:Gadolinium / Q000009:adverse effects; D019786:Gadolinium DTPA; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007676:Kidney Failure, Chronic / Q000503:physiopathology*; D008279:Magnetic Resonance Imaging; D008536:Meglumine / Q000009:adverse effects* / Q000493:pharmacokinetics; D009942:Organometallic Compounds / Q000009:adverse effects* / Q000493:pharmacokinetics; D004369:Pentetic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
chemical_list: D003287:Contrast Media; D004338:Drug Combinations; D009942:Organometallic Compounds; D008536:Meglumine; D004369:Pentetic Acid; D005682:Gadolinium; D003404:Creatinine; D019786:Gadolinium DTPA